Biocryst Pharmaceuticals Announced New Data Which Highlights The Reduction In The Percentage Of Days With Hereditary Angioedema (HAE) Symptoms Among Young Children Initiating Berotralstat In The Apex-P Trial, And The Broad Safety And Efficacy Outcomes Obs